)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Fisher & Paykel Healthcare
Fisher & Paykel Healthcare (FPH) investor relations material
Fisher & Paykel Healthcare AGM 2026 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.AGM 2026 summary25 Aug, 2026
Opening remarks and agenda
Chair welcomed shareholders in person and online, confirmed quorum, and introduced board members and executives.
Meeting agenda included addresses from the Chair and CEO, review of financial statements, resolutions, voting, and a general Q&A session.
Agenda included the Chair's address, CEO's financial and operational update, Q&A on financial statements, and formal resolutions.
Financial performance review
FY26 operating revenue reached NZD 2.31 billion, up 12% in constant currency.
Net profit after tax was NZD 468.5 million, a 28% increase in constant currency.
Gross margin improved by 122 basis points to 63.7%, despite increased costs from tariffs and global events.
Dividend increased by 38% to NZD 0.52 per share, with a payout ratio of 65%.
FY27 guidance projects operating revenue of NZD 2.47–2.57 billion and net profit after tax of NZD 525–565 million.
Board and executive committee updates
Anna Curzon joined the board in February and stood for election.
Margie Apa participated as Future Director under the Future Directors program.
Board composition includes eight named members.
Board composition and director remuneration reviewed, with benchmarking by Mercer.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Fisher & Paykel Healthcare
- Upgraded profit guidance reflects robust demand and margin improvements across key product groups.FPH
Trading update - US tariffs to raise costs in FY2026, delaying gross margin targets by up to three years.FPHTrading update
- FY26 guidance projects strong revenue and profit growth; board director to retire.FPHTrading update
- FY26 revenue and profit guidance increased amid strong growth and margin gains.FPHTrading update
- Revenue and profit up 14% and 24%, with strong margins and positive FY 2027 outlook.FPHH2 2026
- Record half-year revenue and profit growth, with upgraded full-year guidance and margin gains.FPHH1 2026
- Record revenue and profit growth, with robust outlook and strong segment performance.FPHH1 2025
- FY24 saw strong growth, board changes, new products, higher dividends, and global expansion.FPHAGM 2024
- Record revenue and profit growth, with strong outlook despite tariff and seasonal headwinds.FPHH2 2025
Next Fisher & Paykel Healthcare earnings date
H1 202725 Nov, 2026
Fisher & Paykel Healthcare
Next Fisher & Paykel Healthcare earnings date
H1 202725 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Fisher & Paykel Healthcare Corporation Limited (FPH) specializes in designing, manufacturing, and marketing medical device products and systems for use in acute and chronic respiratory care, surgery, and the treatment of obstructive sleep apnea. The company's product portfolio is divided into hospital products, which include devices for invasive ventilation, noninvasive ventilation, nasal high flow therapy, anesthesia, and surgery, and homecare products, which consist of devices for treating obstructive sleep apnea and providing respiratory support at home. The company is headquartered in Auckland, New Zealand, and its shares are listed on the New Zealand Stock Exchange.